C. R. Bard, Cook Medical and Boston Scientific Lead the U.S. Nephrostomy Market

Share Article

The incidence of bladder cancer cases, genealogical malignancies and urinary calculi is expected to drive the U.S. nephrostomy market to over $110 million by 2020, reports iData Research.

The incidence rate of cancer and urinary stones which lead to urinary obstruction will continue to drive PCN procedures and growth in the market

According to an in-depth U.S. urology report, from iData Research, the leading global authority in medical device market research, and the U.S. nephrostomy market is expected to approach over $110 million by 2020. This market includes percutaneous nephrostomy sets, nephrostomy balloon catheters, nephrostomy drainage tubes and ureteral stents. Market growth will be driven by the rise in percutaneous nephrostomy (PCN) procedures.

Growth in procedures will be driven by the incidence of bladder cancer cases, genealogical malignancies and urinary calculi. In 2014 the American Cancer Society’s estimates that there are 74,690 new cases of bladder cancer diagnosed in the United States. “The incidence rate of cancer and urinary stones which lead to urinary obstruction will continue to drive PCN procedures and growth in the market,” says Dr. Kamran Zamanian, CEO of iData.

Nephrostomy balloon catheters will be the fastest growing segment of this market over the next five years. Growth is driven by percutaneous nephrolithotomy procedure numbers and other cases which necessitate balloon dilation of the ureter. The price of nephrostomy balloon catheters is expected to increase slightly through 2020. As the manufacturing companies continue to innovate and develop new products, the price will show a slight increase over the forecast period; but, competitive pressure will mitigate this effect.

Another factor driving the growth of the nephrostomy market in the U.S. is the increase in in-office procedures. Nephrostomy procedures can be performed in both a doctor’s office and a hospital setting. The doctor’s office setting is beneficial to patients because these procedures allow a higher quality of life, as the setting is more comfortable and the procedure often takes slightly less time.

C. R. Bard, is one of the leading manufacturers in the nephrostomy device market in the United States. Bard’s urology division also has focus on on urological drainage, continence, prostate disease management and skin and wound care. Other notable and key competitors leading the nephrostomy market include Cook Medical, Boston Scientific, Applied Medical and Olympus.

For Further Information
The nephrostomy device market segment is part of the U.S. urological devices market report. The global report series on the Markets for Urological Devices covers the U.S., Canada, 15 counties in Europe, Japan, India and China.

The full reports provide a comprehensive analysis including procedure numbers, units sold, market value, forecasts, as well as a detailed competitive market shares and analysis of major players’ success strategies in each market and segment. The reports cover devices used in the treatment of benign prostate hyperplasia (BPH), prostate cancer, and urinary incontinence as well as urinary and kidney stones. Other markets analyzed include urological endoscopes, urodynamic equipment and nephrostomy devices.

Receive a free synopsis of the U.S. Urological Device 2014 Market Research Report

About iData Research
iData Research (http://www.idataresearch.com) is an international market research and consulting group focused on providing market intelligence for medical device and pharmaceutical companies. iData covers research in: Diabetes Drugs, Diabetes Devices, Pharmaceuticals, Anesthesiology, Wound Management, Orthopedics, Cardiovascular, Ophthalmics, Endoscopy, Gynecology, Urology and more.

This report examines the device market for treating of benign prostate hyperplasia (BPH), prostate cancer, urinary and kidney stones, erectile dysfunction and urinary incontinence. Procedures covered include TURP, Laser BPH, Prostatic Stents, TUMT, TUNA, open and laparoscopic.

There is a growing conscientiousness of IMRT as a contributing factor to the rising cost of cancer treatment in the United States. Physicians who have partial ownership of IMRT capital might be incentivized to recommend IMRT as a first-line of treatment.

About Procedure Tracker™
Define and analyze procedure data segmented by State, region, hospital, surgery centre, and physician. Using iData’s customizable dashboard, sort procedure data of your choice to further analyze and research any of the following U.S. procedure categories:

  •     BPH Procedures
  •     LDR Brachytherapy
  •     HDR Brachytherapy
  •     Cryoablation
  •     ESWL
  •     Transurethral
  •     Ureteral Stent Placement
  •     Stone Management
  •     Nephrostomy
  •     Urodynamic
  •     Urinary Incontinence
  •     Incontinence Management Implant
  •     Erectile Dysfunction Management

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Caroline Lau
iData Research
+1 604-266-6933 Ext: 215
Email >
Follow >
iData Research
Like >
iData Research

Follow us on
Visit website